Funded Biotechnology Startups in San Carlos
San Carlos, California has produced a steady stream of biotech funding rounds across multiple years, with the 15 most recent closes spanning May 2020 throu…
San Carlos, California has produced a steady stream of biotech funding rounds across multiple years, with the 15 most recent closes spanning May 2020 through April 2025. The largest disclosed raise in the set is Attovia Therapeutics' $90M Series C in April 2025, followed by Imago BioSciences' $80M undisclosed round in November 2020 and Eiger BioPharmaceuticals' $75M Post-IPO Debt raise in June 2022. The 2024 cohort was the most active by deal count — six rounds in total — though Elegen's $35M Series B was the only labeled institutional round; the others (Onc.AI, MEDiC, CuraSen Therapeutics, Q Bio, Siolta Therapeutics) ranged from $2M to $27M with undisclosed or missing stage designations.
Stage diversity is notable: CellFE completed a $22M Series A in September 2023, two publicly traded companies (Natera, Eiger BioPharmaceuticals) drew post-IPO capital in 2022, and CRISP-HR Therapeutics received $100K in Non-equity Assistance the same year. Therapeutic developers share the dataset with platform businesses in synthetic biology, proteomics, and lab automation.
Most recent rounds
15 shownRelated listings
Frequently asked
What are the largest recent rounds among San Carlos biotech companies in this dataset?
Attovia Therapeutics leads with a $90M Series C closed in April 2025. Imago BioSciences raised $80M in November 2020 and Eiger BioPharmaceuticals raised $75M via Post-IPO Debt in June 2022. Elegen's $35M Series B in May 2024 and Q Bio's $27M Series Unknown in July 2024 are the next largest in the set.
How active was San Carlos biotech funding in 2024 specifically?
Six rounds closed in 2024 per this dataset: Siolta Therapeutics ($12M, March), Elegen ($35M Series B, May), Q Bio ($27M, July), CuraSen Therapeutics ($6M, September), MEDiC ($5M, October), and Onc.AI ($2M, October). Elegen's Series B was the only labeled institutional round; the remaining five carry Series Unknown or no classification.
Which round types appear most often in this San Carlos biotech dataset?
Series Unknown is the most frequent explicit classification, applied to five companies — Onc.AI, MEDiC, CuraSen Therapeutics, Q Bio, and BioCardia. Four rows (Siolta Therapeutics, General Automation Lab Technologies, Imago BioSciences, Nautilus Biotechnology) list no round type. Named venture rounds include Series A (CellFE), Series B (Elegen), and Series C (Attovia Therapeutics), plus two post-IPO instruments from Eiger BioPharmaceuticals and Natera.
Are there post-IPO companies in this dataset still raising capital in San Carlos?
Yes — Eiger BioPharmaceuticals raised $75M in Post-IPO Debt in June 2022 and Natera raised $5M in Post-IPO Equity in March 2022. Both indicate that publicly traded biotech companies headquartered in San Carlos continue to access capital markets and appear alongside earlier-stage peers in this dataset.
How does this dataset split between therapeutics-focused and platform or tools companies?
At least seven companies have a therapeutics orientation — including Attovia Therapeutics, CuraSen Therapeutics, Siolta Therapeutics, Eiger BioPharmaceuticals, Imago BioSciences, BioCardia, and CRISP-HR Therapeutics. The remainder operate in platform or enabling-technology categories: Elegen in synthetic DNA, Nautilus Biotechnology in proteomics, Q Bio in human health data, CellFE in cell engineering, and General Automation Lab Technologies in lab automation.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.